drugset / Trial / NCT05774899
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Phase 1/2
Recruiting
32 enrolled
Glenn J. Hanna
Adenoid Cystic Carcinoma Research Foundation · collabCellestia Biotech AG · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study is to treat patients with NOTCH active advanced adenoid cystic carcinoma (ACC) tumors with a combination or two different oral medications to slow tumor growth and improve survival outcomes. The names of the study drugs involved in this study are: * CB-103 (an oral NOTCH pathway inhibitor) * Abemaciclib (CDK4/6 inhibitor) * Lenvatinib (a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI))
Timeline
- Start
- 2023-06-01
- Primary completion
- 2027-06-01
- Completion
- 2028-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | — | Oral |
| Subject | LIMANTRAFIN | Small molecule | — | Oral |
| Background | Lenvatinib | Small molecule | — | Oral |